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Novelty and Impact 
The prospective evidence on the association between gamma-glutamyltranferase (GGT) and prostate 
cancer risk has not been well studied and is not very clear. In this population-based prospective cohort 
study involving middle-aged Caucasian men, GGT was positively, nonlinearly, and independently 
associated with future prostate cancer risk. The association did not importantly vary across several 
clinical subgroups. Further study is need to evaluate if GGT assays may have any potential relevance in 
the prevention of prostate cancer. 
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Abbreviations 
Body mass index (BMI) 
Confidence interval (CI) 
C-reactive protein (CRP) 
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Finnish Cancer Registry (FCR). 
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Abstract 
Increased circulating serum gamma-glutamyltransferase (GGT) has been linked with an increased risk of 
chronic disease outcomes, including overall and several site-specific cancers. However, the relationship 
of GGT with prostate cancer risk is uncertain. We aimed to assess the prospective association of GGT 
with risk of prostate cancer. Serum GGT activity was assessed at baseline in the Finnish Kuopio Ischemic 
Heart Disease prospective cohort of 2,390 men aged 42-61 years without a history of cancer at baseline. 
We corrected for within-person variability in GGT values using data from repeat measurements taken 
several years apart. During a median follow-up of 24.6 years, 230 cases of prostate cancer occurred. The 
age-adjusted regression dilution ratio for loge GGT was 0.69 [95% confidence interval (CI): 0.63-0.74]. 
Serum GGT was nonlinearly associated with risk of prostate cancer. In age-adjusted Cox regression 
analysis, the hazard ratio (HR) (95% CIs) for prostate cancer in a comparison of the top quartile versus 
bottom quartiles 1-3 of GGT values was 1.43 (1.07 to 1.93; P=0.017), which persisted on adjustment for 
several established cancer risk factors 1.46 (1.06 to 2.02; P=0.020). The association remained unchanged 
on further adjustment for total energy intake, socioeconomic status, physical activity, and C-reactive 
protein. The association did not importantly vary across several clinical subgroups. Gamma-
glutamyltransferase is positively and independently associated with future risk of prostate cancer in a 
middle-aged Finnish male population over long-term follow-up. Further research is needed to understand 
the mechanistic pathways involved and if GGT may have potential relevance in prostate cancer 
prevention. 
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Prostate cancer is the second most common male cancer and it is the second leading cause of death from 
cancer in men. Despite a progressive decline in attributable deaths due to prostate cancer over the past 
decade due to major advances in its treatment and prevention, the absolute number of prostate cancer 
cases is expected to increase because of the ageing population. Prostate cancer therefore remains a vast 
public health problem. Established risk factors for prostate cancer include race, age, and family history.1-3 
Hereditary factors as well as environmental factors such as infections, diet, and hormonal changes, are 
also involved in the pathogenesis of prostate cancer.2 Though these factors explain a large proportion of 
the risk of prostate cancer, its pathogenesis is still not fully established as several other potential risk 
factors appear to be involved. There is therefore a need to critically evaluate putative risk factors that may 
increase our knowledge of prostate cancer development, may have causal or predictive significance, and 
which will help develop preventive and management strategies. Experimental, mechanistic, and 
observational evidence suggests that chronic inflammation2, 4 and oxidative stress5 play a role in the 
aetiopathogenesis of prostate cancer. Gamma-glutamyltransferase (GGT), an index of liver injury and 
used as a clue for excessive alcohol consumption,6 has been shown to be positively associated with 
chronic disease outcomes including cardiovascular disease (CVD), overall and several site-specific 
cancers.7-12 Common pathways implicated to underlie the associations between GGT and these adverse 
disease outcomes are via the pro-oxidant and pro-inflammatory properties of GGT.13 Since similar 
pathways have been implicated for the development of prostate cancer,2, 4  we hypothesized that GGT will 
be associated with an increased risk of prostate cancer. Though several large-scale prospective studies 
have demonstrated associations between GGT and several site-specific cancers,8 there is limited evidence 
on the nature and magnitude of the association of GGT with prostate cancer. In a large Swedish cohort, 
Van Hemelrijck and colleagues found evidence of associations between elevated GGT and risk of various 
site-specific cancers; however, clear evidence of an independent association between GGT and prostate 
cancer risk could not be demonstrated in this study.14 Given the limited data on the relationship between 
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GGT and prostate cancer, we sought to evaluate in detail, the shape, nature, and magnitude of the 
prospective association of GGT with risk of prostate cancer, using a population-based cohort of 2,390 
apparently healthy cancer-free men from eastern Finland. Serial measurements of GGT were performed in 
a subset of participants to help quantify within-person variability in GGT values.  
 
Materials and Methods  
Study population 
The study population were participants in the Kuopio Ischemic Heart Disease (KIHD) risk factor study, a 
prospective population-based cohort study designed to investigate risk factors for vascular disease and 
other chronic outcomes. The study design and recruitment methods have been described in detail 
previously.15 Briefly, participants were a representative sample of men aged 42-61 years living in the city 
of Kuopio and its surrounding rural communities in eastern Finland at the time of baseline examinations. 
There were 3,433 potentially eligible and randomly selected men; and of this number, 2,682 (78%) 
volunteered to participate; 186 did not respond to the invitation and 367 declined to give informed 
consent. Baseline examinations were performed between March 1984 and December 1989. The present 
analysis included a cohort of 2,390 cancer-free men at baseline, with complete information on GGT, 
relevant confounders, and incident prostate cancer cases. The study was approved by the Research Ethics 
Committee of the University of Eastern Finland and each participant provided written informed consent.  
 
Measurement of risk markers 
Collection of blood specimens and biochemical and lipid measurements have been described previously.16 
Briefly, participants fasted overnight, were instructed to abstain from drinking alcohol for at least 3 days, 
and refrain from smoking for at least 12 h prior to assessment. Blood samples were taken in the morning 
and the serum samples were stored frozen at -80 °C before analyses. Serum GGT activity was measured 
using the kinetic method (Thermo Fisher Scientific, Vantaa, Finland) with repeat measurements 
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performed 4 years and 11 years after the baseline measurements in a random subset of participants as 
described previously.7, 17, 18 Fasting plasma glucose (FPG) was measured by the glucose dehydrogenase 
method (Merck, Darmstadt, Germany). C-reactive protein (CRP) with an immunometric assay (Immulite 
High Sensitivity C-Reactive Protein Assay; DPC, Los Angeles, CA, USA). Smoking, blood pressure, and 
total energy intake were assessed as described previously.16, 19 Alcohol consumption was assessed with a 
structured quantity–frequency method using the Nordic Alcohol Consumption Inventory.20 
Socioeconomic status (SES) was measured as a summary index that combined measures of occupation, 
occupational prestige, education, income, material standard of living and housing conditions. A high value 
on the SES index indicated a low socioeconomic state. The energy expenditure of physical activity was 
assessed using the validated KIHD 12-month leisure-time physical activity questionnaire.21, 22 
 
Ascertainment of prostate cancer cases 
Ascertainment of prostate cancer cases has been described in detail in previous reports.23, 24 Briefly, all 
incident cases of prostate cancer that occurred from study enrollment through 2014 were included in the 
present analysis. Cases were derived from the population-based Finnish Cancer Registry (FCR). Every 
diagnosed cancer case in the health care system has been reported in a countrywide and population-based 
manner in Finland since 1953. The coverage of FCR is complete and there were no losses to follow-up.25 
The FCR file containing personal identity codes is annually matched through computerized linkage with 
the national cause of death register at Statistics Finland.  Annual follow-up for cancer was done 
automatically using the personal identifiers. The FCR is regularly linked with the Central Population 
Register to ensure that the personal identity codes are correct. No cases of prostate cancer were diagnosed 
within the first six years of follow-up. All prostate cancer cases were histologically verified.26 
 
Statistical analysis 
Log transformation was conducted for all skewed variables (GGT, CRP, and triglycerides) to approximate 
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normal distributions. Descriptive analyses were performed to summarize the baseline characteristics of 
the participants. Multivariate Cox proportional hazard regression models were used after confirming 
assumptions of proportionality of hazards. To quantify and correct for within-person variability in values 
of GGT, adjusted regression dilution ratios (RDRs) were estimated by regressing available repeat 
measurements on baseline values,27 as described in previous reports.7, 17, 18 To assess the shape of the 
association between GGT and prostate cancer risk, hazard ratios (HRs) confidence intervals (CIs) using 
floating absolute risks,26 were calculated within quartiles of baseline GGT values and plotted against 
mean GGT values within each quartile. This was to allow for comparisons across the groups irrespective 
of the arbitrarily chosen reference category (bottom quartile). As the association showed a nonlinear 
shape, GGT was not modelled continuously, but entered as categories (quartiles) defined according to its 
baseline distribution. Because of the relatively flat risk of prostate cancer across quartiles 1-3 of serum 
GGT values, these categories were combined and served as the reference comparison.. HRs were adjusted 
progressively for (i) age; (ii) body mass index (BMI), smoking status, history of diabetes mellitus, FPG, 
triglycerides, total cholesterol, high-density lipoprotein cholesterol (HDL-C), and alcohol consumption; 
and (iii) total energy intake, SES, physical activity, and CRP. Given the high CVD mortality rate in the 
KIHD cohort, we also performed additional analyses to estimate the baseline cumulative subhazard of 
prostate cancer considering CVD death as a competing outcome to prostate cancer; using the competing-
risks extension of the Cox proportional hazards models, as proposed by Fine and Gray.28 To assess 
whether the association between GGT and prostate cancer risk was modified by relevant individual level 
characteristics, we performed subgroup analyses using interaction tests to assess statistical evidence of 
any differences in hazards. All statistical analyses were conducted using Stata version 13 (Stata Corp, 
College Station, Texas). 
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Results 
Baseline characteristics  
Table 1 summarizes baseline characteristics of the 2,390 participants included in the present analysis. The 
mean age of the participants was 53 (standard deviation, 5) years. Median (interquartile range) GGT value 
was 15 (20-33) U/L. Except for age, SES, history of diabetes, current smoking, fasting plasma glucose, 
and CRP, there were no significant differences in baseline characteristics between prostate cancer cases 
and controls.  
 
Correction for within-person variability in GGT  
Repeat measurements of GGT were taken 4 and 11 years after the baseline measurements during the 
follow-up period in a random sample of 725 participants, yielding a total of 1,450 repeat measurements of 
GGT. Overall, the age-adjusted RDR of loge GGT was 0.69 (95% CI: 0.63 to 0.74), which suggests that 
the association of GGT with prostate cancer using one-off or baseline measurements of GGT could under-
estimate the risk by [(1/0.69)-1]*100 = 45%.  
 
Gamma-glutamyltransferase and risk of prostate cancer 
During a median (interquartile range) follow-up of 24.6 (16.8-26.9) years, 230 cases of prostate cancer 
(annual rate 4.52/1000 person-years at risk, 95% CI: 3.98 to 5.15) were recorded. A nonlinear association 
was observed between circulating GGT and prostate cancer risk (Figure 1). Comparing the top quartile 
versus combined bottom quartiles 1-3 of GGT, the age-adjusted HR for prostate cancer was 1.43 (95% 
CI: 1.07 to 1.93; P=0.017), which remained consistent 1.46 (95% CI: 1.06 to 2.02; P=0.020) following 
further adjustment for risk factors for prostate cancer. The results remained unchanged on additional 
adjustment for total energy intake, socioeconomic status, physical activity, and CRP 1.50 (95% CI: 1.08 
to 2.07; P=0.015). After correction for within-person variability in GGT values, the similarly adjusted 
HRs were 1.68 (95% CI: 1.10 to 2.58; P =0.017), 1.74 (95% CI: 1.09 to 2.76; P =0.020), and 1.79 (95% 
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CI: 1.12 to 2.87; P = 0.015) respectively (Table 2). A total of 558 CVD deaths occurred during follow-
up. In analyses including CVD death as a competing risk event, the HRs were 1.40 (95% CI: 0.98 to 1.99; 
P = 0.067) and 1.62 (95% CI: 0.97 to 2.72; P = 0.067) comparing the top quartile versus combined 
bottom quartiles 1-3 of baseline and usual GGT values respectively. The associations generally did not 
vary significantly by levels or categories of several clinically relevant characteristics and other risk 
markers (P for interaction ≥ 0.10 for each; Figure 2). A subgroup analysis could not be performed for 
diabetes status, because only three men with a prevalent history of diabetes developed prostate cancer 
during follow-up (Table 1). 
 
Discussion 
In this population of apparently healthy middle-aged Finnish men, we have shown that high values of 
GGT were nonlinearly and independently associated with an increased risk of prostate cancer over long-
term follow-up. Analysis correcting for within-person variability in GGT values suggested that the 
association using baseline measurements of GGT with prostate cancer risk was almost half as strong as it 
otherwise would be using usual levels of GGT. Given the high CVD mortality rate in our study cohort 
which might have hindered our event of interest, the association between GGT and prostate cancer was 
less robust when CVD death was adjusted for as a competing risk event. This was not a surprising finding 
as GGT was independently associated with CVD mortality in the cohort.  The association between GGT 
and prostate cancer remained generally consistent across several clinically relevant characteristics. 
 
Comparison with previous studies 
Several large-scale observational cohorts studies based in general population settings have shown an 
increased risk of overall and site-specific cancers with elevated circulating serum GGT activity. In a 
cohort of over 500,000 individuals within the Swedish AMORIS prospective study, elevated GGT was 
shown to be associated with an increased risk of developing overall and several site-specific cancers.14 In 
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in a large population-based cohort of 79,279 healthy Austrian men, Strasak and colleagues demonstrated 
GGT to be significantly associated with overall cancer risk as well as cancers of the digestive, respiratory, 
and urinary organs.29 To provide a better indication of the relevance of GGT to cancer risk, given the 
inconsistencies in some of these previous studies; our group has recently conducted a pooled 
comprehensive analysis of available published prospective evidence on these associations in one 
comprehensive analysis.8 We showed that elevated GGT activity was associated with an increased risk of 
overall cancer, cancers of male genital organs, and cancers of digestive organs. In addition, it was 
demonstrated that the relationship of GGT with overall cancer risk was consistent with a log-linear shape. 
There are however limited published data on the associations of GGT and prostate cancer risk. To our 
knowledge, only two studies have evaluated the association; Tsuboya and colleagues found no evidence 
of an association between GGT and prostate cancer in their cohort of Japanese adults aged 40-79 years.30 
Van Hemelrijck and colleagues in the Swedish AMORIS prospective cohort study, found no evidence of 
an association between GGT modelled as a categorical variable and prostate cancer risk.14 However, 
when a linear relationship was assumed, a weak association was demonstrated.  In stratified analysis, the 
authors also observed a stronger risk between GGT and prostate cancer in men with higher glucose levels, 
which was not observed in this study. In contrast, we were able to assess the shape of the GGT-prostate 
cancer relationship and observed a nonlinear relationship. Given the nonlinear shape of the association, 
GGT was modelled as a categorical variable and the findings showed evidence of an association between 
elevated GGT and an increased risk of prostate cancer. A subsidiary analysis using GGT as a continuous 
variable also showed evidence of statistically significant associations (data not shown but available on 
request).  
 
Possible Explanations for Findings 
It is uncertain if GGT has a direct role in the aetiology of prostate cancer or may just be a marker of 
underlying pathology. Several potential mechanisms have been hypothesized. A broad body of evidence 
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suggests the role of chronic inflammation in prostate carcinogenesis.2, 4 Multiple factors have been 
suggested to contribute to the chronic inflammation process   within the prostate and these include 
infections, dietary factors, and hormonal changes.2 Elevated GGT activity may contribute to the 
inflammatory process within the prostate, as it mediates interconversion of the glutathione-containing 
inflammatory mediator leukotriene C4 into leukotriene D4.31 Indeed, given the long follow-up between 
baseline measurements of GGT and the occurrence of prostate cancer in our study, there is a likelihood 
that the effects of inflammation on prostate cancer are mediated through a chronic process. However, our 
observed GGT-prostate cancer association was independent of CRP, a well-known marker of low-grade 
chronic inflammation; which may suggest that other processes apart from inflammation may underlie the 
aetiology. Gamma-glutamyltransferase has pro-oxidant properties32 and is a source of reactive oxygen 
species (ROS), which is known to be involved in cellular growth, proliferation, and apoptosis.33, 34 The 
persistent production of ROS may contribute to prostatic cancer development, progression, or invasion. 
Gamma-glutamyltransferase activity has been demonstrated to be increased in malignant lesions and 
suggested to confer survival advantages on tumour cells.35 Elevated GGT activity may also be linked to 
the increased risk of prostate cancer via hyperglycemia.36 Van Hemelrijck and colleagues in their study, 
showed a relatively stronger risk of prostate cancer with elevated GGT activity in individuals with higher 
glucose levels.14 In our analyses, however, the observed association was independent of fasting glucose 
levels and there was also no evidence of effect modification by glucose levels. Finally, the link between 
GGT and prostate cancer may be via lifestyle and environmental factors such as alcohol consumption, 
diet, pollutants, and smoking; which influence circulating GGT activity37-39 and may have direct roles in 
carcinogenesis.40, 41 Indeed in our study, stratified analysis by amount of alcohol consumption showed 
elevated GGT to be statistically significantly associated with prostate cancer risk in men who consumed 
more alcohol, but the results were not statistically significant for men who consumed less alcohol; 
however, there was no statistically significant evidence of effect modification. Several mechanistic 
pathways have been suggested to underlie the association between GGT and prostate cancer risk; 
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however, most of these factors were accounted for in our multivariate analyses, therefore it may be 
unlikely that some of these pathways or factors would be essentially involved in the pathophysiology. 
Further large-scale studies are needed to replicate these associations and the aetiopathogenic pathways 
postulated to underlie the association deserve confirmation in mechanistic studies. 
 
Implications of Findings 
Our study extend previous findings on the potentially deleterious role of increasing circulating GGT 
activity on future risk of several chronic disease outcomes.7-12 We have demonstrated that GGT is also 
associated with an increased risk of prostate cancer in addition to overall cancer and several site-specific 
cancers in the general male population. Whether GGT is just a marker of underlying cancer risk, a 
putative risk factor for cancer risk, or causal therapeutic target, is still yet to be ascertained. Further 
investigation of any potential relevance of GGT in prostate cancer prevention strategies is warranted.  In 
the absence of such evidence, individuals with persistent elevated circulating GGT detected during 
routine liver panel tests may need further clinical evaluation. 
 
Strengths and Limitations 
Several strengths of our study deserve mention. These include the large-scale population-based 
prospective cohort design with selection of participants who were representative of the general 
population; the high response rate and no loss to follow-up; and reliable ascertainment of prostate cancer 
outcomes using an established cancer registry which employs unique personal identification codes. We 
had information on a comprehensive panel of confounding factors which allowed adequate adjustment for 
several risk factors for prostate cancer. The mean follow-up period in this study was sufficiently long to 
ascertain the risk for prostate cancer and the first cases of prostate cancer only occurred six years after 
baseline examinations, which minimised reverse causation and selection biases. Serial measurements of 
GGT made within a subset of individuals over time were available, enabling correction for within-person 
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variability in GGT activity over the long period of follow-up. We employed comprehensive analyses 
which included assessment of the shape of the association and stratified analyses by several clinical 
relevant characteristics. The study findings need to be interpreted in light of the following limitations: (i) 
the study included only Caucasian men and therefore the results cannot be generalised other races; (ii) 
despite adjustment for a comprehensive panel of lifestyle and biochemical risk markers, there is still a 
potential for residual confounding given the observational nature of the study; and (iii) we were unable to 
evaluate effect modification by history of diabetes on the association due to the low number of prostate 
cancer cases in men with a history of diabetes.   
 
Conclusions 
Gamma-glutamyltransferase is positively and independently associated with future risk of prostate cancer 
in a middle-aged Finnish male population over long-term follow-up. Further research is needed to 
understand the mechanistic pathways involved and if GGT may have any potential relevance in prostate 
cancer prevention. 
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Figure legends 
Figure 1. Hazard ratios for prostate cancer, by quartiles of baseline values of gamma-glutamyltransferase 
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A, adjusted for age; B, adjusted for age, body mass index, smoking status, history of diabetes, fasting 
glucose, triglycerides, total cholesterol, high-density lipoprotein cholesterol, and alcohol consumption 
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Figure 2. Hazard ratios for baseline values of gamma-glutamyltransferase and prostate cancer risk by 
several participant level characteristics 
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A, adjusted for age; B, adjusted for age, body mass index, smoking status, history of diabetes, fasting 
glucose, triglycerides, total cholesterol, high-density lipoprotein cholesterol, and alcohol consumption; 
CI, confidence interval; GGT, gamma-glutamyltransferase; HR, hazard ratio; *, P-value for interaction 
Hazard ratios compare the top quartile versus combined bottom quartiles 1-3 of GGT 
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Table 1. Baseline Participant Characteristics 
 
  
Overall (N=2,390) 
Mean (SD) or n (%) 
 
Without prostate cancer 
(N=2,160) 
Mean (SD) or n (%) 
 
With prostate cancer 
(N=230) 
Mean (SD) or % 
 
 
P-value 
Loge GGT (U/L) 3.13 (0.65) 3.13 (0.65) 3.14 (0.67) 0.768 
     
Questionnaire/Prevalent conditions     
Age at survey (years) 53.2 (5.0) 53.1 (5.0) 53.9 (4.5) 0.019 
Alcohol consumption (g/week) 74.6 (134.7) 75.3 (137.9) 68.2 (98.7) 0.446 
Total energy intake, kJ/day 9,853 (2,589) 9,835 (2,591) 10,023 (2,566) 0.295 
Socioeconomic status 8.54 (4.23) 8.63 (4.21) 7.75 (4.34) 0.003 
History of diabetes 96 (4.0) 93 (4.3) 3 (1.3) 0.028 
Current smokers 753 (31.5) 698 (32.3) 55 (23.9) 0.009 
History of hypertension 731 (30.6) 673 (31.2) 58 (25.2) 0.063 
     
Physical measurements     
BMI (kg/m2) 26.9 (3.6) 26.9 (3.6) 26.7 (3.1) 0.404 
SBP (mmHg) 134 (17) 134 (17) 133 (15) 0.356 
DBP (mmHg) 89 (11) 89 (11) 88 (10) 0.792 
Physical activity (kj/day) 1,546 (1,486) 1,527 (1,465) 1,727 (1,667) 0.053 
     
Lipid markers     
Total cholesterol (mmol/l) 5.91 (1.09) 5.91 (1.09) 5.94 (1.10) 0.679 
HDL-C (mmol/l) 1.30 (0.30) 1.29 (0.30) 1.31 (0.31) 0.697 
Loge triglycerides (mmol/l) 0.12 (0.51) 0.12 (0.51) 0.12 (0.52) 0.898 
     
Metabolic and inflammatory 
markers 
    
Fasting plasma glucose (mmol/l) 5.36 (1.28) 5.38 (1.33) 5.77 (1.94) 0.033 
Serum creatinine (µmol/1) 89.6 (20.8) 89.4 (21.5) 91.7 (70.7) 0.239 
Loge CRP (mg/l) 0.34 (0.97) 0.36 (0.99) 0.69 (1.01) 0.020 
 
 BMI, body mass index; CRP, C-reactive protein; DBP, diastolic blood pressure; GGT, gamma-glutamyltransferase HDL-C, high-density 
lipoprotein cholesterol; SD, standard deviation; SBP, systolic blood pressure; 
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Table 2. Associations of baseline and usual levels of gamma-glutamyltransferase with prostate cancer  
 
Serum GGT 
(U/L) 
Events/Total Model 1  Model 2  Model 3  
  HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
Baseline GGT values 
Q1- Q3 (5-33) 170 / 1,826 ref  ref  ref  
Q4 (> 33) 60 / 564 1.43 (1.07 to 1.93) 0.017 1.46 (1.06 to 2.02) 0.020 1.50 (1.08 to 2.07) 0.015 
Usual GGT values 
Q1- Q3 (5-33) 170 / 1,826 ref  ref  ref  
Q4 (> 33) 60 / 564 1.68 (1.10 to 2.58) 0.017 1.74 (1.09 to 2.76) 0.020 1.79 (1.12 to 2.87) 0.015 
 
Model 1: Adjusted for age 
Model 2: Model 1 plus BMI, smoking status, history of diabetes, fasting glucose, triglycerides, total cholesterol, high-density 
lipoprotein cholesterol, and alcohol consumption 
Model 3: Model 2 plus total energy intake, socioeconomic status, physical activity, and C-reactive protein 
 
 
